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Abstract
Background: Mucopolysaccharidosis type III (MPS III, Sanfilippo syndrome) is a lysosomal storage disorder caused
by a deficiency of one of the enzymes involved in the degradation of heparan sulfate.
MPS III is characterized by progressive mental deterioration resulting in severe dementia. A number of potentially
disease-modifying therapies are studied. As preservation of cognitive function is the ultimate goal of treatment,
assessment of cognitive development will be essential in order to evaluate treatment efficacy. However, no large
scale studies on cognitive levels in MPS III patients, using formal psychometric tests, have been reported.
Methods: We aimed to assess cognitive development in all 73 living patients with MPS III in the Netherlands.
Results: Cognitive development could be assessed in 69 patients. In 39 of them developmental level was
estimated > 3 months and formal psychometric testing was attempted. A remarkable variation in the intellectual
disability was detected.
Conclusions: Despite special challenges encountered, testing failed in only three patients. The observed broad
variation in intellectual disability, should be taken into account when designing therapeutic trials.
Background
Mucopolysaccharidosis type III (MPS III, Sanfilippo syn-
drome) is an autosomal recessive lysosomal storage dis-
order caused by a deficiency of one of the four enzymes
involved in the degradation of the glycosaminoglycan
heparan sulfate. Four subtypes of MPS III, caused by
deficiency of one of these four enzymes, are recognised.:
MPS III types A, B, C and D. Signs and symptoms and
course of the disease in the different subtypes are, how-
ever, indistinguishable.
MPS III is a neurodegenerative disorder characterized
by an initial symptom free period followed by progres-
sive intellectual decline, finally resulting in severe
dementia. Severe behavioural problems are a predomi-
nant symptom in most patients, characterized mainly by
extremely hyperactive behaviour [1]. Other symptoms
include sleeping problems, recurrent diarrhoea, frequent
ear, nose and throat infections, hearing and visual
impairment and epilepsy. Patients usually die at the end
of the second or the beginning of the third decade of
life, although longer survival has been reported in
patients with an attenuated form of MPS III[2-4].
The rate of decline of intellectual capacities varies
widely in patients with MPS III [2,5-8]. Patients with the
severe or ‘classical’ phenotype of MPS III have a normal
to near normal development during the first two years
of life, followed by a slowing of development and full
stagnation of development at around the age of 3 to 4
years, and finally regression of cognitive capacities [6,9].
Patients usually become fully dependent on care early in
their teenage years.
Patients with a more attenuated phenotype may have a
stable intellectual disability for many years. These
patients, who also have a longer preservation of motor
functions, may live well into adulthood [8,10,11].
Testing the level of cognitive development in patients
with MPS III is necessary in order to quantify the
decline of intellectual abilities. However, no studies
using formal psychometric testing in a large group of
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This information on the natural course is important as
new disease-modifying therapies for MPS III are cur-
rently developed with preservation of cognitive function
as the main therapeutic goal[12-14].
We therefore aimed to assess the cognitive develop-
ment in all living MPS III A, B and C patients in the
Netherlands, and provide data from this relatively large
and unbiased cohort.
Methods
Recruitment of patients
All living patients ever diagnosed with MPS III in the
Netherlands since enzyme testing became available
(1967) were identified by retrieving the data from the
combined registry of the four diagnostic centres in the
Netherlands [15]. Parents or legal representatives were
asked to participate in this study via physicians who had
requested the initial diagnostic studies. The study was
approved by the Medical Ethical Committee of the
AMC, Amsterdam.
Developmental assessment
Developmental assessment was done by a single psy-
chologist (JPM), experienced in testing patients with
intellectual disabilities. Patients were tested using an
appropriate test for their estimated developmental age.
All patients with an estimated developmental age above
3 months were tested within the scope of this study.
To exclude any effects of training, testing was per-
formed at least one year after a previous developmental
test, if applicable. To optimize testing in these patients
with often behavioral problems in addition to the intel-
lectual disabilities, patients were tested in a familiar
environment (at home or at their day care centre).
Three different developmental tests were used. All
tests were performed according to their guidelines.
The Dutch version of the Bayley Scales of Infant
Development II (BSID-II-NL) was used in patients with
an estimated developmental age between 4 months and
3 years [16]. The Snijders-Oomen Nonverbal intelli-
gence test - Revised (SON-R 2 1/2-7), a validated Dutch
non-verbal developmental test, was used in patients with
an estimated developmental age between 3 years and 6
years [17]. Finally, the Dutch version of the Wechsler
Intelligence Scale for Children, third edition (WISC-III-
NL) was used in patients with an estimated develop-
mental age above 6 years [18].
The BSID-II-NL was chosen as it is the most recent
version of the Bayley Scales of Infant Development
available and validated in the Netherlands. It is consid-
ered a reliable and valid test by COTAN, the Test Advi-
sory Board for the Dutch Psychologists Institute, and is
frequently used in research. The Snijders-Oomen
Nonverbal Intelligence Test - Revision (SON-R 2.5-7)
was chosen as it received a good evaluation from
COTAN and is available and validated in Dutch. The
internationally often used Wechsler Preschool and Pri-
mary Scale of Intelligence, an alternative for SON-R,
was considered unreliable in Dutch by COTAN and at
the time of this study the Dutch version of the Third
Edition of the was not yet released. Finally, the WISC-
III-NL was used as this is the most recent version of the
Wechsler Intelligence Scale for Children available in the
Netherlands. The WISC-III-NL is considered reliable
and valid by COTAN.
All tests have been used previously in studies on cog-
nitive development in children and adolescents with
intellectual disabilities [19].
Results
Patients
In total, 73 MPS III patients were alive at the time of
this study.
Thirty-seven patients had MPS IIIA. Of them, 32 were
assessed for inclusion in this study as two patients who
had received a Hematopoietic Stem Cell Transplantation
(HSCT) were excluded and families of three other
patients refused to participate. Twenty-three patients
had MPS IIIB. All patients participated in the study.
Thirteen MPS IIIC patients were alive at the time of the
study. One MPS IIIC patient was lost to follow-up,
while the remaining 12 patients participated in this
study. In total, 69 patients were assessed for feasibility
for developmental testing (Figure 1).
All patients were untreated, except for three patients
(2 patients with MPS IIIA for less than 6 months and
one patient with MPS IIIC for a period of 3 years), tak-
ing genistein, a soy-bean derived isoflavone, which may
ameliorate disease severity in MPS III by inhibition of
GAG synthesis [20].
MPS IIIA patients
Of the participating 32 MPS IIIA patients, 16 patients
were assessed as having a developmental age below 3
months and were excluded for further testing. In the
remaining 16 patients, the WISC-III-NL was performed
in 2 patients, the SON-R 2 1/2-7 in 3 and BSID-II-NL
in 11. Results are shown in Figure 2.
MPS IIIB patients
Eleven patients of the 25 participating MPS IIB patients
were assessed as having a developmental age below 3
months. Testing was attempted in all remaining 12
patients. Testing failed in three of them due to extreme
anxiety, aggressive behavior and refusal to cooperate.
These patients were excluded. Of the remaining 9
patients, the BSID-II-NL was performed in 8 patients
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in 2 patients. Results are shown in Figure 3.
MPS IIIC patients
All 13 participating MPS IIIC patients had a develop-
mental age above 3 months. BSID-II-NL was performed
i n9p a t i e n t sa n dt h eS O N - R21 / 2 - 7i n3p a t i e n t s .
Results are shown in Figure 4.
Difficulties in cognitive testing in patients with MPS III
Patients in our study frequently showed extreme hyper-
active behavior and fidgeting. This often resulted in
noisy behavior, throwing of test material, mouthing and
biting of test materials and unwillingness to perform
specific tasks.
Hyperactive behavior in MPS III patients is compli-
cated by additional attention deficits. Patients are easily
distracted and can frequently only perform short tasks,
further complicated by motor apraxia, which was
observed in a number of patients. This was particularly
problematic in specific assignments necessitating more
detailed instructions. Patients were found to be much
more interested in persons compared to the materials
used in the tests, further complicating testing.
Aggressive behavior may be an additional symptom in
MPS III patients. In this cohort, severe aggressive beha-
vior was only encountered in one patient with MPS IIIB
and resulted in failure to test.
Excessive anxiety is also a symptom in MPS III
patients. In this study, anxiety resulted in failed testing
in one patient with MPS IIIB.
Stereotypic behavior and stereotypic language were
seen in several patients. Stereotypic language in combi-
nation with aphasia significantly complicated language
assessment in these patients. In addition, many patients
tended to perseverate.
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Figure 1 Flow diagrams of MPS III patients included in the study.
Figure 2 Developmental age in patients with MPS IIIA (n = 33).
The straight dotted line indicates the normal developmental
pattern.
Figure 3 Developmental age in patients with MPS IIIB (n = 23).
The straight dotted line indicates the normal developmental
pattern.
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disabilities in several patients. One patient suffered from
retinitis pigmentosa resulting in a decreased vision,
complicating testing.
Finally, a number of patients showed a disharmonic
developmental pattern. This could be reliably assessed
in all patients tested with the WISC-III-NL and SON-R
2 1/2-7 and for patients tested with the BSID-II-NL test
with a developmental age between 12 and 30 months. In
23% of patients the disharmonic developmental pattern
was found to be significant, according to the test
guidelines.
Discussion and conclusions
We assessed cognitive development in 69 patients with
MPS III and we could perform formal assessment of
psychometric developmental in 39 patients with an esti-
mated developmental level > 3 months. A remarkable
variation in the intellectual disability was detected.
Patients with the classical severe phenotype of MPS III
generally reached a maximal developmental age of
approximately 3-4 years (Figure 5), while patients with a
more attenuated phenotype showed a considerably
wider spectrum with some patients, reaching even a
developmental age of 10 yrs in one patient. Patients
with an attenuated phenotype, especially MPS IIIB
patients, may have a long period of stable intellectual
disability even well into adulthood, without any signs of
regression [4].
Formal assessment of cognitive functions in patients
with MPS III poses several major challenges. Hyperac-
tive behavior, anxiety and aggressive behavior are a pre-
dominant symptom in MPS III [1,21]. Concurrent
concentration problems [1], present in the majority of
patients with MPS III, further complicate testing and
assignments requiring longer instructions proved to be
difficult for most patients. A test such as the BSID-II,
which consists of many separate short tasks, was found
t ob et h em o s ts u i t a b l ef o rt h e s ee a s i l yd i s t r a c t e d
patients. The more recently developed BSID-III appears
to be even more suitable for testing this group of
patients as it consists of five distinct scales of develop-
ment (Cognitive, Language, Motor, Social Emotional
and Adaptive Behavior Scale), while the BSID-II consists
of three scales (Mental, Motor and Behavior Scales).
However, this test was not validated in Dutch at the
time of this study.
Twenty-three percent of the tested patients showed a
significant disharmonic developmental pattern. This
phenomenon is often detected in patients with organic
mental retardation. For example in patients with trisomy
21 speech is usually spared, even in the presence of
extensive dementia [22]. A disharmonic profile is char-
acteristic in patients with MPS III, as intellectual decline
almost invariably precedes regression of motor functions
[2,6,23].
Developmental testing may be hampered by physical
disabilities observed in MPS patients [21]. In our cohort
this was not a significant problem. Some patients
showed mild hearing loss, but this did not complicate
testing. Only one patient, with visual disabilities due to
retinitis pigmentosa, could not complete some of the
test assignments due to a physical disability.
Figure 4 Developmental age in patients with MPS IIIC (n = 12).
The straight dotted line indicates the normal developmental
pattern.
Figure 5 Developmental age in all tested patients with MPS III
according to age. The straight dotted line indicates the normal
developmental pattern.
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tive developmental in MPS III patients, developmental
testing failed in only three. Failure was due to extreme
anxiety, severe aggressive behavior and refusal to coop-
erate. In all other patients, parents and care-givers
expressed the opinion that patients showed a reliable
reproduction of their development during the
assessment.
Testing in a familiar environment such as home or
day-care center is likely to improve the success of psy-
chometric testing in patients with MPS III. Patients with
MPS III are easily distracted and any change in environ-
ment can increase behavioural disturbances, resulting in
an autistic behavior [24].
Developmental assessment in untreated patients with
MPS III characterizes the natural history of MPS III
[21], which appears to be remarkably variable. Patients
with the severe MPS III phenotype show a slowing of
development from the age of 2-4 years onwards. Subse-
quently, a maximal developmental level of approximately
3.5-4 years is reached followed by a regression of devel-
opmental level from the age of 4-6 years [6,9]. Although
this phenotype is the most well known and reported
phenotype of MPS III, an increasing number of patients
with an attenuated course of MPS III is reported
[3,4,7,8,10,11].
A limitation of our study is that we only obtained
cross-sectional data on cognitive development in MPS
III. Longitudinal studies in patients with different MPS
III subtypes and different phenotypic severity will be
needed to be able to assess efficacy of treatment in indi-
vidual patients. In addition, we did not study hyperactive
and agressive behavior and anxiety, which are common
behavioral symptoms in MPS III as our study was
focused only on cognitive development. Behavioral dis-
turbances may also influence the reliability of cognitive
testing. By testing the patients in a familiar environment
which often reduces the behavioral problems, we tried
to reduce this potential confounder as much as possible.
Currently, several disease-modifying treatments for
MPSIII are studied. These therapies include substrate
reduction therapy, HSCT, intrathecal enzyme replace-
ment therapy and gene therapy [25]. In order to achieve
optimal efficacy, treatment should be initiated before
irreversible CNS damage occurs. Early diagnosis is
therefore essential. Increasing awareness of MPS III in
the medical community may help to diagnose MPS III
patients as early as possible. However since developmen-
tal delay is usually the presenting symptom in MPS III
patients, CNS damage is almost invariably present at
diagnosis. Therefore, identification of patients in the
pre-symptomatic period can only be achieved by screen-
ing of patients at risk (e.g. sibs) or by newborn screen-
ing. A major criterion for inclusion of a disease in
screening programs is adequate knowledge on the nat-
ural history of the disorder [26]. Our study provides
information on the spectrum of cognitive disabilities in
patients with MPS III, which helps to understand the
variability in the natural course of this devastating
inborn error of metabolism.
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